bpc+tb blend
BPC-157 plus TB-500, often called the Wolverine stack, is marketed for injury recovery. A small knee-pain report included BPC-157 plus TB4, but it did not show that the pair repairs tissue or works better than BPC-157 alone.
BPC-157 + a TB-labeled ingredient
- BPC-157 + a TB-labeled ingredient
- TB4 versus fragment identity needs confirmation
What does TB-500 mean in this blend?
A product name is not enough to identify the thymosin ingredient. Full-length thymosin beta-4 and a short fragment are different materials. A result obtained with TB4 cannot simply be assigned to every vial labeled TB-500.
What should the product record identify?
The sequence or exact chemical identity, the form of BPC-157, the amount of each ingredient, the route and the tested finished formulation. A combined milligram total conceals the ratio. A mass measurement may help distinguish molecules, but it does not establish the full quality or safety of the preparation.
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceHas this exact combination been tested?
A retrospective knee-pain report included four BPC-157/TB4 recipients. The cited records contain no controlled result for a chemically specified marketed BPC/TB fixed blend.
Exact combination · one uncontrolled report
Literature and registry record set
PubMed and public trial records.
A retrospective knee-pain report included four BPC-157/TB4 recipients. The cited records contain no controlled result for a chemically specified marketed BPC/TB fixed blend.
- The cited records contain no published or registered controlled study of a BPC-157/TB4 or TB-500 fixed blend.
What did the human knee study actually show?
Three of four combination recipients reported improvement. Without randomization or imaging, the report cannot show whether the blend affected cartilage or tendon repair.
Does the study show the blend beats BPC-157?
The report followed small, nonrandomized groups. It cannot isolate TB4's contribution, distinguish treatment effects from other changes, or establish that a marketed fixed vial matches the injections studied.
Knee-pain series · four combination recipients
Retrospective human case series
Lee E, Padgett B. Alternative Therapies in Health and Medicine, 2021. PMID 34324435.
Three of four respondents who received BPC-157 plus TB4 reported knee-pain improvement. This retrospective telephone follow-up had no randomized comparator and did not document structural repair. It cannot establish an added benefit from TB4 or validate a marketed fixed vial.
Read the original sourceDoes one ingredient work locally and the other systemically?
No human study mapped separate local and systemic effects for the two ingredients. The underlying repair literature uses different substances, models, and routes.
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceWhat are the side effects?
The available report is too small and brief to estimate side-effect rates or repeated-use risk. FDA’s BPC-157 review notes limited human safety information and concerns about impurities and immune reactions.
Does a small human report establish safety?
Four recipients cannot reveal uncommon adverse events or long-term effects, and the report does not validate other routes.
FDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA describes limited human safety information for BPC-157 and concerns about impurities, product characterization and immune reactions.
Read the original sourceFDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceIs there a proven ratio, route or recovery timeline?
The knee report used local injections and did not compare fixed ratios or treatment courses. It provides no protocol for a subcutaneous vial, tendon injury, postoperative recovery, or training soreness.
Knee-pain series · four combination recipients
Retrospective human case series
Lee E, Padgett B. Alternative Therapies in Health and Medicine, 2021. PMID 34324435.
Three of four respondents who received BPC-157 plus TB4 reported knee-pain improvement. This retrospective telephone follow-up had no randomized comparator and did not document structural repair. It cannot establish an added benefit from TB4 or validate a marketed fixed vial.
Read the original sourceExact combination · one uncontrolled report
Literature and registry record set
PubMed and public trial records.
A retrospective knee-pain report included four BPC-157/TB4 recipients. The cited records contain no controlled result for a chemically specified marketed BPC/TB fixed blend.
- The cited records contain no published or registered controlled study of a BPC-157/TB4 or TB-500 fixed blend.
Studies and sources
FDA · BPC-157 evidence review
Regulatory safety assessment
FDA · BPC-157 evidence review
The FDA review separates laboratory and animal findings, limited human reports and marketed combination products. A product being sold or discussed in an advisory meeting does not establish a demonstrated benefit, a safe formulation or FDA approval.
Read the original sourceKnee-pain series · four combination recipients
Retrospective human case series
Lee E, Padgett B. Alternative Therapies in Health and Medicine, 2021. PMID 34324435.
Three of four respondents who received BPC-157 plus TB4 reported knee-pain improvement. This retrospective telephone follow-up had no randomized comparator and did not document structural repair. It cannot establish an added benefit from TB4 or validate a marketed fixed vial.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA describes limited human safety information for BPC-157 and concerns about impurities, product characterization and immune reactions.
Read the original sourceExact combination · one uncontrolled report
Literature and registry record set
PubMed and public trial records.
A retrospective knee-pain report included four BPC-157/TB4 recipients. The cited records contain no controlled result for a chemically specified marketed BPC/TB fixed blend.
- The cited records contain no published or registered controlled study of a BPC-157/TB4 or TB-500 fixed blend.
Why is bpc+tb blend in A tier?
Direct combination evidence is limited to four recipients in an uncontrolled knee-pain report. No controlled trial measures tissue healing, comparative benefit over BPC-157, or repeated-use safety.